LUBAC’s newly discovered role in the Nature Communications study revolves around quality control: something every well-functioning business - or body system - needs to conduct successfully.
LUBAC regulates the quality of the immune respond by preventing autoimmune cells from continuing through the stages of development when they respond to “self,” also known as the host’s own healthy cells that don’t need immune cell mounting a response against them.
“We're excited by the prospect that this new checkpoint may be important for ensuring autoimmune T cells are not allowed to complete their development," Teh said.
Current treatments for autoimmune diseases suppress the entirety of the immune system, making people more vulnerable to infection from any bacteria and viruses that they encounter. With this new finding, though, the potential for a more targeted treatment grows, by only targeted T cells with dysfunctional LUBAC.
New applications in the future involve new treatments for autoimmune diseases and diseases caused by mutations in the gene coding for LUBAC, which past research has connected to rare immune diseases.
Source: Walter and Eliza Hall Institute